139 related articles for article (PubMed ID: 8981333)
21. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
Rachev E
Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
[TBL] [Abstract][Full Text] [Related]
22. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
[TBL] [Abstract][Full Text] [Related]
23. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
Lübbert H; Nauert C
Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
[TBL] [Abstract][Full Text] [Related]
24. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
25. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
26. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate.
Frenkel Y; Kopernik G; Lazer S; Tugendreich D; Zmira N; Oettinger M; Tendler R; Serr DM
Maturitas; 1994 Nov; 20(1):31-6. PubMed ID: 7877518
[TBL] [Abstract][Full Text] [Related]
27. [Comparative study of the acceptability of a new estradiol Tx 11323 (A) gel and a transdermal matrix system].
Gelas B; Thébault J; Roux I; Herbrecht F; Zartarian M
Contracept Fertil Sex; 1997 Jun; 25(6):470-4. PubMed ID: 9280552
[TBL] [Abstract][Full Text] [Related]
28. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages.
Evans SF; Davie MW
Clin Endocrinol (Oxf); 1996 Jan; 44(1):79-84. PubMed ID: 8706298
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women.
Hilditch JR; Lewis J; Ross AH; Peter A; van Maris B; Franssen E; Charles J; Norton P; Dunn EV
Maturitas; 1996 Jul; 24(3):177-84. PubMed ID: 8844631
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of Menorest in two positive-controlled studies.
Pornel B
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
[TBL] [Abstract][Full Text] [Related]
31. Estrogen replacement therapy and the estraderm transdermal system.
Youngkin EQ
Nurse Pract; 1990 May; 15(5):19-26, 31. PubMed ID: 2342664
[TBL] [Abstract][Full Text] [Related]
32. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
33. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms.
Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J
Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch].
Sajtos B; Herold J; Winkler UH; Schindler AE
Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835
[TBL] [Abstract][Full Text] [Related]
35. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
37. Transdermal hormonal replacement therapy with transdermal progestin every second month.
Lindgren R; Risberg B; Hammar M; Berg G
Maturitas; 1995 Jun; 22(1):25-30. PubMed ID: 7666813
[TBL] [Abstract][Full Text] [Related]
38. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with Systen, a new transdermal form of hormone replacement therapy.
Corson SL
Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():36-44. PubMed ID: 8499958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
